Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
03/01/2023* 08:30 EST Earnings Call Q4 2022 -- -- --
03/01/2023* -- Results Q4 2022 -- -0.60 --
11/03/2022 08:30 EST Earnings Call Q3 2022 -- -- --
11/03/2022 -- Results Q3 2022 -0.57 -0.84 32.40%
08/09/2022 08:30 EST Earnings Call Q2 2022 -- -- --
08/09/2022 -- Results Q2 2022 -0.92 -0.76 -20.68%
05/10/2022 08:30 EST Earnings Call Q1 2022 -- -- --
05/10/2022 -- Results Q1 2022 -0.78 -0.91 13.86%
*Estimated Date/Time

Earnings

Next Report Date 03/01/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 11/03/2022
Beat/Miss Upgrade
Return Since 4.24%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
URL https://www.intracellulartherapies.com
Investor Relations URL https://ir.intracellulartherapies.com/
HQ State/Province New York
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Small Cap/Growth
Next Earnings Release Mar. 01, 2023 (est.)
Last Earnings Release Nov. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
204.8%
-71.95%
-4.04%
-21.34%
201.2%
-7.32%
64.59%
3.32%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.26%
--
--
--
--
--
--
--
44.13%
-70.83%
585.7%
68.40%
62.89%
-39.62%
52.41%
3.44%
22.20%
22.57%
29.44%
4.45%
3.43%
-3.07%
4.25%
15.81%
29.71%
--
--
--
2.32%
-52.61%
56.55%
22.71%
-70.56%
As of December 02, 2022.

Profile

Edit
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
URL https://www.intracellulartherapies.com
Investor Relations URL https://ir.intracellulartherapies.com/
HQ State/Province New York
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Small Cap/Growth
Next Earnings Release Mar. 01, 2023 (est.)
Last Earnings Release Nov. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
WGMCX 54.11M USD 3.94%
XPH 7.666M USD 3.53%
DLRHX 20.94M USD 2.58%
LADQX 63.33M USD 2.57%
FRBRX 21.06M USD 2.53%
ATL1726 11.35M USD 2.13%
WMCVX 24.32M USD 1.97%
IHE 7.603M USD 1.78%
GAM 16.18M USD 1.61%
BTEC 752956.0 USD 1.29%
HQL 4.225M USD 1.08%
HQH 9.671M USD 1.04%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter ITCI Tweets